CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia

The advent of CD19-specific chimeric antigen receptor (CAR) T cells has proven to be a powerful asset in the arsenal of cancer immunotherapy of acute lymphoblastic leukemia and certain B cell lymphomas. However, a sizable portion of patients treated with CD19-CAR T cells relapse with CD19-negative c...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrer, Dennis C., Schuler, Gerold, Dörrie, Jan, Schaft, Niels
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600602/
https://www.ncbi.nlm.nih.gov/pubmed/31195686
http://dx.doi.org/10.3390/ijms20112764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600602/
https://www.ncbi.nlm.nih.gov/pubmed/31195686
http://dx.doi.org/10.3390/ijms20112764

Ejemplares similares